TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2407002

Group type: EXPERIMENTAL
Intervention: UW solution
Number of subjects: 257

Group type: COMPARATOR
Intervention: Euro-Collins solution
Number of subjects: 257
Study: 7428411

Group type: EXPERIMENTAL
Intervention: 250 mg naproxen, 400 mg ibuprofen, and 25 mg indomethacin twice daily with 500 mg naproxen suppository at night
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naproxen tablet and suppository phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Indomethacin capsule and naproxen suppository phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of two non-steroidal anti-inflammatory drugs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naproxen suppositories
Number of subjects: 30
Study: 31769585

Group type: EXPERIMENTAL
Intervention: Neuramis® Volume Lidocaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: VYC‐20L
Number of subjects: 88
Study: 30176883

Group type: EXPERIMENTAL
Intervention: Manual Therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Educational Group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 27
Study: 26914484

Group type: EXPERIMENTAL
Intervention: Vitamin B12 testing (referral for a vitamin B12 blood test)
Number of subjects: 5131

Group type: COMPARATOR
Intervention: No vitamin B12 testing (no referral)
Number of subjects: 5131
Study: 25306870

Group type: EXPERIMENTAL
Intervention: RetinSphere (topical retinoid combination)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30
Study: 23857683

Group type: EXPERIMENTAL
Intervention: Mycobacteria growth indicator tube (MGIT) 960 system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Löwenstein-Jensen medium
Number of subjects: 0
Study: 22167112

Group type: EXPERIMENTAL
Intervention: 8 weeks of nicotine replacement therapy (NRT; nicotine patch) + 6 sessions of motivational interviewing (MI)
Number of subjects: 430

Group type: COMPARATOR
Intervention: NRT + standard care
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: NRT (nicotine patch)
Number of subjects: 430
Study: 18505180

Group type: EXPERIMENTAL
Intervention: AZT+ddC
Number of subjects: 3195

Group type: COMPARATOR
Intervention: AZT monotherapy
Number of subjects: 3195

Group type: COMPARATOR
Intervention: AZT+ddl
Number of subjects: 3195
Study: 17175484

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 0
Study: 14578869

Group type: EXPERIMENTAL
Intervention: Recombinant HCV E1 (20 mug) administered intramuscularly at weeks 0, 4, 8, 12, and 24.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (alum only) administered intramuscularly at weeks 0, 4, 8, 12, and 24.
Number of subjects: 35
Study: 10714552

Group type: COMPARATOR
Intervention: G-CSF from day 0 to day 13 after HDCT (arm A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: G-CSF from day 0 to day 6 and GM-CSF from day 7 to day 13 (arm B)
Number of subjects: 34
Study: 9760788

Group type: EXPERIMENTAL
Intervention: Sera from ILD patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sera from AFL patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sera from DIPF patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control sera from healthy individuals
Number of subjects: 43
Study: 1376841

Group type: EXPERIMENTAL
Intervention: Isradipine (n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Metoprolol (n = 26)
Number of subjects: 52
Study: 3899368

Group type: EXPERIMENTAL
Intervention: 40 mg Nimodipine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31619305

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (specific antipsychotics not detailed) over an 18-month period
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Genetic variations related to obesity-risk genes
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: GWAS analysis
Number of subjects: 765
Study: 29278718

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy for Obesity (CRT-O)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 80
Study: 25800045

Group type: EXPERIMENTAL
Intervention: Topical Citrullus colocynthis extract oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23861132

Group type: EXPERIMENTAL
Intervention: Bilirubin levels in patients with CAD (n=145)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (n=76)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Direct bilirubin levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Total bilirubin levels
Number of subjects: 221
Study: 22781295

Group type: EXPERIMENTAL
Intervention: LACJ therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + Jinghuaweikang 3 capsules)
Number of subjects: 565

Group type: COMPARATOR
Intervention: LACB therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg)
Number of subjects: 565

Group type: COMPARATOR
Intervention: LAC therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: LACJ therapy
Number of subjects: 565

Group type: COMPARATOR
Intervention: LACB therapy
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Detection of antibiotic-resistant genes
Number of subjects: 565
Study: 20219104

Group type: EXPERIMENTAL
Intervention: Top Grub card game and healthy eating curriculum
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1133
Study: 18657673

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Normal sinus rhythm at follow-up
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at follow-up
Number of subjects: 118
Study: 15876828

Group type: EXPERIMENTAL
Intervention: Ultrapure bicarbonate dialysis (BD)
Number of subjects: 64

Group type: COMPARATOR
Intervention: On‐line predilution hemofiltration (HF)
Number of subjects: 64
Study: 12577049

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 207
Study: 10234558

Group type: EXPERIMENTAL
Intervention: Anesthesiologists
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (other physicians)
Number of subjects: 68
Study: 8894500

Group type: EXPERIMENTAL
Intervention: 1.0 mg NN623
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg A4166
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg NN623
Number of subjects: 0
Study: 1927487

Group type: EXPERIMENTAL
Intervention: Yunfujing
Number of subjects: 131

Group type: COMPARATOR
Intervention: Armillaria mellea vabi (control)
Number of subjects: 131
Study: 6804161

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with 50 micrograms or less of ethinyl estradiol
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Preparation containing 20 micrograms ethinyl estradiol
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Preparation containing 400 micrograms norethisterone acetate
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Norethisterone preparations
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing preparations
Number of subjects: 2430
Study: 31919724

Group type: EXPERIMENTAL
Intervention: PRIDE intervention (literacy-sensitive, provider-focused health communication)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard diabetes education (control)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PRIDE intervention
Number of subjects: 410
Study: 31603428

Group type: EXPERIMENTAL
Intervention: I-CBT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stepped care (I-CBT followed by face-to-face CBT if needed)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Therapists' group with largest median reduction of fatigue
Number of subjects: 100
Study: 27660368

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hip extension (HE) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study: 25559915

Group type: EXPERIMENTAL
Intervention: Resistance training three times weekly
Number of subjects: 131

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 131
Study: 24165896

Group type: EXPERIMENTAL
Intervention: Turmeric gargle
Number of subjects: 80

Group type: COMPARATOR
Intervention: Povidone-iodine gargle
Number of subjects: 80
Study: 22475046

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1155
Study: 19893122

Group type: EXPERIMENTAL
Intervention: Therapeutic education on CHF topics (general information, symptoms, dietary nutrition, medicative therapy)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Therapeutic education
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no therapeutic education)
Number of subjects: 57
Study: 18179756

Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide
Number of subjects: 178
Study: 15133425

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 5804
Study: 11795438

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) for 3 months
Number of subjects: 0
Study: 9501267

Group type: EXPERIMENTAL
Intervention: Phenylalanine‐complemented amino acid supplement (increased blood phenylalanine concentrations to 1000-1300 mumol/L for 3 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 16
Study: 7655966

Group type: EXPERIMENTAL
Intervention: Carbon dioxide as a contrast medium for intra-arterial digital subtraction lower limb angiography
Number of subjects: 11
Study: 2679938

Group type: EXPERIMENTAL
Intervention: Intervention group (health education promoting a cholesterol-lowering diet, smoking cessation, weight control, physical activity, treatment of arterial hypertension)
Number of subjects: 19409

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19409
Study: 1098358

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 international units daily for 3 months)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 29699792

Group type: EXPERIMENTAL
Intervention: GARDASIL (quadrivalent human papillomavirus vaccine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 100
Study: 26229044

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo taping (PT)
Number of subjects: 14
Study: 24286482

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transobturator tape (TOT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mixed urinary incontinence subgroup
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence subgroup
Number of subjects: 100
Study: 22274550

Group type: EXPERIMENTAL
Intervention: Milk test meal
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Casein test meal
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whey test meal
Number of subjects: 17
Study: 20337618

Group type: EXPERIMENTAL
Intervention: ramosetron 0.3 mg (n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: ondansetron 4 mg (n = 42)
Number of subjects: 84
Study: 18354860

Group type: EXPERIMENTAL
Intervention: Implantable hemodynamic monitoring (IHM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15842968

Group type: EXPERIMENTAL
Intervention: Bare metal stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting stents
Number of subjects: 0
Study: 11712327

Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 23
Study: 9424913

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 270
Study: 7899034

Group type: EXPERIMENTAL
Intervention: Motion detection system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement aftereffect (MAE)
Number of subjects: 0
Study: 3596789

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 5819

Group type: EXPERIMENTAL
Intervention: Inclusion of the beta-blocker oxprenolol
Number of subjects: 5819

Group type: EXPERIMENTAL
Intervention: Better blood pressure control
Number of subjects: 5819

Group type: EXPERIMENTAL
Intervention: Presence of ST segment depression and complete left bundle branch block in entry ECG
Number of subjects: 5819

Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 5819
Study: 2539345

Group type: COMPARATOR
Intervention: CCNU alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CCNU with BENZO
Number of subjects: 44
Study: 30406291

Group type: EXPERIMENTAL
Intervention: 2-day psychoeducation group
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 2-week psychoeducation group
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study: 29019894

Group type: EXPERIMENTAL
Intervention: Late-course concurrent chemoradiotherapy (CCRT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sequential therapy (SCRT)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Late-course concurrent chemoradiotherapy (CCRT) in pT3-4 pN1-3 cM0 subgroup
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sequential therapy (SCRT) in pT3-4 pN1-3 cM0 subgroup
Number of subjects: 155
Study: 26320194

Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 100

Group type: COMPARATOR
Intervention: aripiprazole and risperidone
Number of subjects: 100
Study: 23509175

Group type: EXPERIMENTAL
Intervention: Single-cleansing with 4.0% chlorhexidine
Number of subjects: 29760

Group type: EXPERIMENTAL
Intervention: Multiple-cleansing with 4.0% chlorhexidine
Number of subjects: 29760

Group type: COMPARATOR
Intervention: Dry and clean cord care (comparison)
Number of subjects: 29760

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29760
Study: 21733566

Group type: EXPERIMENTAL
Intervention: High dose Catumaxomab (10, 20, 50, and 100 μg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low dose Catumaxomab (10 μg)
Number of subjects: 45
Study: 19811362

Group type: EXPERIMENTAL
Intervention: GABA-rich Chlorella (20 mg as gamma-aminobutyric acid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18221627

Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14979754

Group type: EXPERIMENTAL
Intervention: Prepotent Response Inhibition and Resistance to Distractor Interference
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Resistance to Proactive Interference
Number of subjects: 220
Study: 11498310

Group type: EXPERIMENTAL
Intervention: Diprivan (AstraZeneca, UK)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Recofol (Leiras Oy, Finland)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol (Abbott)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diprofol (Taro, Israel)
Number of subjects: 120
Study: 9754979

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1.2 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Eformoterol with placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eformoterol with budesonide
Number of subjects: 12
Study: 7828695

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms.day‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3414919

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 0
Study: 31383439

Group type: EXPERIMENTAL
Intervention: Reflexology (30 min per session, once per day for 12 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no reflexology)
Number of subjects: 72
Study: 27521028

Group type: EXPERIMENTAL
Intervention: short‐pulsed 1064‐nm‐Nd:YAG laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: no laser treatment (control group)
Number of subjects: 20
Study: 25924674

Group type: EXPERIMENTAL
Intervention: Finding My Way Intervention (iCBT)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 188
Study: 23407407

Group type: EXPERIMENTAL
Intervention: Physiotherapy alone (neck-specific exercises with a cognitive-behavioral approach)
Number of subjects: 63

Group type: COMPARATOR
Intervention: ACDF followed by physiotherapy
Number of subjects: 63
Study: 21442808

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chinese medicine (Tianqi Tongjing Capsule)
Number of subjects: 58
Study: 19674485

Group type: EXPERIMENTAL
Intervention: Task-oriented circuit class training (CCT) applied in groups of 4 to 6 patients, two times a week for 12 weeks.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual individual, face-to-face physiotherapy (Control group).
Number of subjects: 220
Study: 16474093

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment for both humans and buffaloes in Jishan
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Praziquantel treatment for humans only in Hexi
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Chemotherapy for buffaloes in Jishan
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Mathematical modeling
Number of subjects: 1000000
Study: 15472458

Group type: EXPERIMENTAL
Intervention: 12-week structured education and exercise program (Group E)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No intervention (Group C)
Number of subjects: 35
Study: 11761389

Group type: EXPERIMENTAL
Intervention: 0.015-inch skin grafts
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.025-inch skin grafts
Number of subjects: 0
Study: 9404589

Group type: EXPERIMENTAL
Intervention: Special outpatient clinic
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Screening and advice group
Number of subjects: 2351

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2351
Study: 8495764

Group type: EXPERIMENTAL
Intervention: Buserelin acetate (400 micrograms three times per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/d)
Number of subjects: 0
Study: 3120167

Group type: EXPERIMENTAL
Intervention: hp GRF 1‐44 amide
Number of subjects: 7

Group type: COMPARATOR
Intervention: bromocriptine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: stress tests (insulin‐induced hypoglycaemia/glucagon)
Number of subjects: 7

Group type: COMPARATOR
Intervention: TRH, GnRH and glucose tests
Number of subjects: 7
Study: 29604403

Group type: EXPERIMENTAL
Intervention: Slow loaded breathing (SLB)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Deep breathing control (CON)
Number of subjects: 32
Study: 27696440

Group type: EXPERIMENTAL
Intervention: 1200 mg raltegravir (q.d.) alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1200 mg raltegravir co-administered with 400 mg atazanavir (q.d.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 400 mg atazanavir (q.d.)
Number of subjects: 14
Study: 24832482

Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping (EAM) derived bipolar voltage criteria
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voltage cutoff <0.2 mV
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voltage cutoff <0.45 mV
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bipolar voltage cutoff of 0.27 mV on DE CMRI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Voltage range 0.2-0.45 mV
Number of subjects: 20
Study: 22571342

Group type: EXPERIMENTAL
Intervention: MG98 125 mg/m2 with Interferon-α-2β 9 MIU (continuous schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MG98 200 mg/m2 with Interferon-α-2β 9 MIU (intermittent schedule)
Number of subjects: 0
Study: 20861218

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) 43 g/d for 12 weeks
Number of subjects: 182

Group type: COMPARATOR
Intervention: Corn-soy blend (CSB) 71 g/d for 12 weeks
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 182
Study: 18628466

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 173

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 173
Study: 16133554

Group type: EXPERIMENTAL
Intervention: 0.2 g BBR three times daily for 3 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: CsA without BBR co-administration
Number of subjects: 52
Study: 12177103

Group type: EXPERIMENTAL
Intervention: Regimen A (carboplatin, etoposide, and vincristine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined induction and radiotherapy (HFEBRT at a dose of 72 Gy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regimen B (cisplatin, etoposide, cyclophosphamide, and vincristine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Response to chemotherapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regimen A (induction)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regimen B (induction)
Number of subjects: 32
Study: 10540010

Group type: EXPERIMENTAL
Intervention: Exercise to the anaerobic threshold with Bipap STD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study: 7887757

Group type: EXPERIMENTAL
Intervention: Stress condition (cognitive task for 20 minutes)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control condition (rest quietly for 20 minutes)
Number of subjects: 44
Study: 1977258

Group type: EXPERIMENTAL
Intervention: Cyclosporin A, 5 mg/kg/day for 10 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 10
Study: 366720

Group type: EXPERIMENTAL
Intervention: 0.5% Marcain
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 31
Study: 31126062

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus casei variety rhamnosus; n = 42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No probiotics (n = 39)
Number of subjects: 81
Study: 27884805

Group type: EXPERIMENTAL
Intervention: Flexible Policy
Number of subjects: 3795